FIELD: biochemistry.
SUBSTANCE: invention relates to biochemistry, in particular to a pharmaceutical composition for treating a human VEGF mediated disease, comprising a recombinant VEGF antibody or antigen-binding fragment thereof, as well as a kit containing said composition. Also disclosed is a method of treating a human VEGF mediated disease in a subject using said composition.
EFFECT: invention enables effective treatment of VEGF human mediated disease.
10 cl, 15 dwg, 12 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| VEGF INHIBITING STABLE AND SOLUBLE ANTIBODIES | 2009 |
|
RU2531523C9 |
| STABLE AND SOLUBLE ANTIBODIES INHIBITING VEGF | 2009 |
|
RU2588467C2 |
| STABLE AND SOLUBLE ANTIBODIES INHIBITING VEGF | 2016 |
|
RU2648152C2 |
| STABLE AND SOLUBLE ANTIBODIES INHIBITING VEGF | 2019 |
|
RU2747735C2 |
| HUMANIZING RABBIT ANTIBODIES USING A UNIVERSAL ANTIBODY FRAMEWORK | 2018 |
|
RU2696202C1 |
| HUMANIZATION OF RABBIT ANTIBODIES USING THE UNIVERSAL ANTIBODY FRAME | 2014 |
|
RU2652907C2 |
| HUMANISATION OF RABBIT ANTIBODIES USING UNIVERSAL ANTIBODY SCAFFOLD | 2009 |
|
RU2567006C2 |
| STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα | 2018 |
|
RU2678120C1 |
| STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα | 2009 |
|
RU2567100C2 |
| STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα | 2009 |
|
RU2653753C1 |
